Overall, GLP-1s impact on appetite is a game-changer, making it easier to stick to a healthy lifestyle and achieve my dietary goals

Serious Warning Signs Severe abdominal pain: Especially if sudden onset, radiating to back, or with vomiting (possible pancreatitis, occurred in 0.3% of patients) Severe vomiting: If unable to keep any fluids down for 24 hours (dehydration risk) Signs of dehydration: Dark urine, dizziness on standing, confusion, decreased urination (acute kidney injury risk) Vision changes: Blurred vision, eye pain (rare but requires evaluation) Rapid heart rate: Persistent heart rate over 100 at rest (some increase normal, average 2-4 bpm, but sustained tachycardia needs evaluation) Suicidal thoughts: Any thoughts of self-harm (under 1% occurrence but requires immediate support) Severe allergic reaction: Difficulty breathing, throat swelling, severe rash (anaphylaxis requires emergency care) Lump in neck: Especially with difficulty swallowing (thyroid concern, rare but part of class warning) Trust your instincts

Phase 3 trials currently underway Seven TRIUMPH trials are testing retatrutide across multiple indications: TRIUMPH-1 : Obesity without diabetes TRIUMPH-2 : Type 2 diabetes TRIUMPH-3 : Obesity with type 2 diabetes TRIUMPH-4 : Obesity with knee osteoarthritis (COMPLETED, 28.7% weight loss) TRIUMPH-5 : Obstructive sleep apnea TRIUMPH-6 and 7 : Additional indications These trials will provide the definitive data for the commercial dosage chart
H., Yang, W
But visceral fat is metabolically active and quickly regenerates after treatment stops without ongoing intervention
GIP receptor activation in the brain may contribute to appetite regulation through mechanisms distinct from GLP-1 signaling, potentially explaining tirzepatide's superior weight loss compared to GLP-1 monoagonists